Clinical Trial Update: Intermittent Dosing Of Selumetinib In Childhood NF1 Associated Tumours [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial data on intermittent dosing of selumetinib in children with Neurofibromatosis Type 1-related tumours, including plexiform neurofibromas and opti…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Neurofibromatosis Type
• Optic Nerve Glioma
• Plexiform Neurofibroma

Drugs mentioned

• Selumetinib (selumetinib)

Snippet

Sponsor: Great Ormond Street Hospital for Children NHS Foundation Trust | Conditions: Neurofibromatosis Type 1, Plexiform Neurofibroma | Phase 1, Phase 2 | Status: COMPLETED